Search results
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...
Benzinga· 5 days agoDupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
Stress can be "the triggering factor" for skin problems. Dermatologists share their advice. - WDEF
WDEF Chattanooga· 4 days agoDermatologist Dr. Afton Cobb says she sees patients all the time who notice “the triggering factor...
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
Benzinga· 5 days agoNOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive
9 Analysts Have This To Say About Incyte - Incyte (NASDAQ:INCY)
Benzinga· 3 days agoIncyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma ...
Amalgamated Bank Decreases Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
ETF DAILY NEWS· 2 days agoAmalgamated Bank decreased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 6.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and ...
Vanguard Personalized Indexing Management LLC Raises Position in Incyte Co. (NASDAQ:INCY)
ETF DAILY NEWS· 7 days agoVanguard Personalized Indexing Management LLC boosted its stake in Incyte Co. (NASDAQ:INCY – Free Report) by 30.4% during the fourth quarter, according to its most recent 13F filing with the ...
Howard W. Robin Sells 16,650 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
ETF DAILY NEWS· 4 days agoNektar Therapeutics (NASDAQ:NKTR – Get Free Report) CEO Howard W. Robin sold 16,650 shares of the company’s stock in a transaction on Friday, May 17th. Following the completion of the transaction ...
AbbVie (NYSE:ABBV) Shares Down 0.1%
ETF DAILY NEWS· 18 hours agoAbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price dropped 0.1% during mid-day trading on Thursday . The stock traded as low as $157.76 and last traded at $159.38. Approximately 903,885 ...
Jonathan Zalevsky Sells 7,355 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
ETF DAILY NEWS· 4 days agoNektar Therapeutics (NASDAQ:NKTR – Get Free Report) insider Jonathan Zalevsky sold 7,355 shares of the stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average ...